Company: CYTK
Filing Date: 2025-09-22
Form Type: 8-K
Source: 0001193125-25-209437
Chunk: 4

Company: CYTOKINETICS INC
Filing Date: 2025-09-22
Form: 8-K
Item: Item 1.01
Chunk 4
---
 used (i) to support the potential commercial launch of aficamten; (ii) to continue and expand the development program for aficamten; (iii) to advance its development and research pipeline; and (iv) for general corporate purposes, including potentially to retire the remaining 2027 Notes before or at maturity of those notes that are not exchanged and refinanced pursuant to the Note Exchange Transactions, and for working capital.

The Company expects to use a portion of the net proceeds from the offering and expects to issue 2,168,806 shares of its common stock in exchange for approximately $399.5 million aggregate principal amount of the 2027 Notes in privately negotiated transactions (the “ Note Exchange Transactions”) entered into concurrently with the pricing of the offering.

The above description of the Indenture and the Notes is a summary and is not complete. A copy of the Indenture and the form of the certificate representing the Notes are filed as exhibits 4.1 and 4.2, respectively, to this Current Report on Form 8-K, andthe above summary is qualified by reference to the terms of the Indenture and the Notes set forth in such exhibits.

  Item 2.03.      Creation of a Direct Financial Obligation or an Off-Balance Sheet Arrangement.  

The disclosure set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

  Item 3.02.      Unregistered Sales of Equity Securities.  

The disclosure set forth in Item 1.01 above is incorporated by reference into this Item 3.02. The Notes were issued to the initial purchasers in reliance upon Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act”), in transactions not involving any public offering. The Notes were resold by the initial purchasers to persons whom the initial purchasers reasonably believe are “qualified institutional buyers,” as defined in, and in accordance with, Rule 144A under the Securities Act. The Company relied on these exemptions from registration based in part on representations made by the initial purchasers in the purchase agreement dated September 16, 2025 by and among the Company and the initial purchasers.

The Notes and the shares of common stock issuable upon conversion of the Notes, if any, have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Any shares of the Company’s common stock that may be